英文标题：First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.

中文标题：一线adagrasib（ADA）联合帕博利珠单抗（PEMBRO）治疗晚期/转移性KRAS G12C突变NSCLC患者：KRYSTAL-7研究II期部分的结果

讲者：Pasi A. Jänne, PhD | Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

英文标题：TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).

中文标题：TROPION-Lung02研究：Dato-DXd联合帕博利珠单抗±铂类化疗（Pt-CT）作为晚期非小细胞肺癌（aNSCLC）的一线（1L）治疗

讲者：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine

英文标题：CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC): A randomized, single-blind, multicenter phase 3 study.

中文标题：CAMPASS研究：贝莫苏拜单抗联合安罗替尼对比帕博利珠单抗一线治疗晚期非小细胞肺癌(aNSCLC)：一项随机、单盲、多中心III期研究

讲者：上海市胸科医院 韩宝惠

英文标题：Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.

中文标题：zipalertinib在既往接受过含铂化疗（无论是否接受过埃万妥单抗治疗）的EGFR外显子20 插入突变非小细胞肺癌（NSCLC）患者中的疗效

讲者：Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center

英文标题：SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.

中文标题：SOHO-01：BAY 2927088 用于既往接受过治疗但未接受HER2靶向治疗或未接受过任何治疗的晚期HER2突变NSCLC患者的安全性和有效性研究

讲者：香港中文大学 Herbert H. Loong

英文标题：Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

中文标题：赛沃替尼（Savo）联合奥希替尼（Osi）对比化疗（Chemo）治疗在表皮生长因子受体突变（EGFRm）及MET基因扩增（METamp）的晚期非小细胞肺癌（NSCLC）患者中，经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后疾病进展（PD）的疗效：来自随机Ⅲ期SACHI研究的结果

讲者：上海市胸科医院 陆舜

英文标题：Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

中文标题：Patritumab deruxtecan (HER3-DXd) 用于接受第三代EGFR-TKI治疗后耐药的EGFR突变晚期非小细胞肺癌 (NSCLC) 患者：III期HERTHENA-Lung 02研究

讲者：香港中文大学  莫树锦

英文标题：Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.

中文标题：芦康沙妥珠单抗（sac-TMT）用于既往接受过治疗的晚期EGFR突变非小细胞肺癌患者：来自OptiTROP-Lung03随机研究的结果

讲者：中山大学肿瘤防治中心  张力

英文标题：Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.

中文标题：一种靶向c-Met蛋白的抗体药物偶联物（ADC）Telisotuzumab Adizutecan（ABBV-400；Temab-A）用于治疗晚期表皮生长因子受体突变（EGFR-MT）非鳞状（NSQ）非小细胞肺癌（NSCLC）患者的Ⅰ期研究结果

讲者：David Ross Camidge, MD, PhD | University of Colorado Cancer Center

英文标题：Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).

中文标题：来自Ⅱ期SAVANNAH研究随机亚组的疗效及中枢神经系统（CNS）结果：比较赛沃替尼（Savo）联合奥希替尼（Osi）与赛沃替尼联合安慰剂（PBO）的对比研究。

讲者：Benjamin Philip Levy, MD, FASCO | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

英文标题：Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).

中文标题：贝莫苏拜单抗联合化疗，随后序贯联合安罗替尼一线治疗局部晚期或转移性鳞状非小细胞肺癌的III期研究

讲者：中国医学科学院肿瘤医院  石远凯

英文标题：Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).

中文标题：血基于血浆标志物引导的非小细胞肺癌（NSCLC）一线化疗免疫治疗的适应性研究

讲者：Julia K. Rotow, MD | Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

英文标题：Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.

中文标题：非小细胞肺癌患者免疫化疗给药时间对无进展生存期和总生存期影响的随机试验研究

讲者：湖南省肿瘤医院 张永昌

英文标题：Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.

中文标题：缺氧反应型CEA CAR-T 细胞疗法治疗复发或难治性非小细胞肺癌：一项单臂、开放标签、Ⅰ期试验

讲者：华中科技大学同济医学院附属同济医院  魏双

英文标题：S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).

中文标题：S1900E：一项旨在评估共突变对sotorasib治疗既往接受过治疗的Ⅳ期/复发性KRAS G12C突变（MUT）非鳞状（Non-sq）非小细胞肺癌（NSCLC）疗效影响的Ⅱ期研究，（由ECOG-ACRIN主导的Lung-MAP子研究）

讲者：Sukhmani Kaur Padda, MD | Fox Chase Cancer Center/Temple Health

英文标题：Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.

中文标题：olomorasib联合免疫治疗一线治疗KRAS G12C突变晚期NSCLC患者的安全性和有效性：LOXO-RAS-20001试验更新结果

讲者：Konstantin H. Dragnev, MD | Dartmouth Cancer Center

英文标题：Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.

中文标题：Sosimerasib单药治疗既往接受过治疗的KRAS G12C突变非小细胞肺癌患者：II期研究的主要结果

讲者：中国医学科学院肿瘤医院  王洁